Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.
- Six Specialized Modalities Testing CDMO Readiness In 2026
- Green Supply Chains Rarely Start With A Pledge; Target Waste Instead
- The Real Reason We Haven't Fully Automated Cell Therapy Yet
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Smart Scaling For Cell And Gene Therapies
To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.
-
The Rescue Option: Course Correcting Struggling Clinical Trials
The willingness to seek expert support from Rescue CROs when clinical trials face critical challenges is not a sign of weakness but a demonstration of accountability and commitment to excellence.
-
A Beginner's Guide To Sf9 Culture In Stirred-Tank Bioreactors
Learn about the workflow steps for Sf9 cell expansion, virus preparation, and protein production in stirred-tank bioreactors, including GFP expression.
-
Lyophilization To Enable Drug Products Containing Labile Molecules
Develop lyophilized formulations to overcome stability challenges and significantly extend the shelf life of sensitive therapeutic products.
-
Ensuring Viral Safety Through Multiplexed Adventitious Virus Detection
Gain a targeted look at multiplex digital PCR that detects diverse human viral contaminants with speed, sensitivity, and precision. Learn how high‑multiplex workflows support QC needs.
-
Handle Single-Use Technology Biopharma Waste: Data Sharing, Collaboration
Learn more about data sharing and collaboration to enable a better environmental impact of single-use technologies (SUTs) and quantifying the single-use plastic waste generated when manufacturing mAbs.
-
Analytical Method Release And Stability Platform For RNA Drug Substance
We offer comprehensive analytical support across the R&D space, including method development, validation, process characterization, in-process testing, process validation, and GMP release testing.
-
Evaluating The Expression Patterns Of Multiple Inhibitory Receptors
Discover how an innovative approach to interpreting T-cell exhaustion and inhibitory receptor expression is paving the way for innovative therapeutic approaches aimed at rejuvenating T-cell function.
-
Make Your Production Sites Adaptable And More Efficient
Pharma faces mounting complexity and tighter margins, demanding agile, future-ready production. Discover how smart manufacturing enables faster adaptation and continuous therapy availability.
-
Unraveling The Complexity Of Cell Therapy: Advancements And Challenges
Cell therapy has emerged as a powerful tool for addressing critical medical challenges, but its rapid evolution necessitates a clear regulatory framework and consistent terminology.
NEWSLETTER ARCHIVE
- 03.05.26 -- Regulatory, Payer & Distribution Insights For CGT Success
- 03.05.26 -- Process Engineering's Key Role In Sterile Injectable Facility Design
- 03.04.26 -- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- 03.03.26 -- STREAM Edition: Breakthrough In HER2 Immunotherapy For PMO With Paul Romness
- 03.03.26 -- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Powering AI And Synthetic Biology In Therapy Design
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections